Q32 Bio develops targeted biotherapeutics that re-regulate immune function to treat severe autoimmune and inflammatory diseases. Their lead candidates, Bempikibart and ADX-097, are designed to modulate adaptive and innate immune responses, respectively, addressing conditions such as atopic dermatitis and ANCA-Associated Vasculitis.
Funding
$42M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many severe autoimmune and inflammatory diseases lack effective treatments that can precisely re-regulate immune function without causing broad immunosuppression. Current therapies often fail to address the underlying immune dysregulation, leading to inadequate disease control and significant side effects.
Solution
Q32 Bio develops targeted biotherapeutics designed to rebalance the immune system and treat severe autoimmune and inflammatory diseases. Their lead candidate, Bempikibart (ADX-914), is a fully human anti–interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody (mAb) that re-regulates adaptive immune function by blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling. The second candidate, ADX-097, is a humanized anti-C3d mAb fusion protein designed to restore complement regulation through a novel, tissue-targeted mechanism, modulating the innate immune system. These biologics aim to provide targeted immune modulation, improving outcomes for patients with conditions such as atopic dermatitis and ANCA-Associated Vasculitis.
Target Audience
The primary target audience includes patients suffering from severe autoimmune and inflammatory diseases, as well as physicians and clinical researchers specializing in immunology and autoimmune disorders.
Features
- Bempikibart (ADX-914): Fully human anti-IL-7Rα antagonist mAb
- Bempikibart: Blocks IL-7 and TSLP signaling to re-regulate adaptive immune function
- Bempikibart: Currently in Phase 2 clinical trials for atopic dermatitis (AD) and alopecia areata (AA)
- ADX-097: Humanized anti-C3d mAb fusion protein
- ADX-097: Restores complement regulation through tissue-targeted mechanism
- ADX-097: Currently in an open-label Phase 2 renal basket clinical trial and planned Phase 2 clinical trial in ANCA-Associated Vasculitis (AAV)